Vita Life SciencesASX:VLS -1.20%83 Cyclically Adjusted PB Ratio is 3.58 as of Jul. 04, 2026, which is 8% above its 10-year median of 3.32. GuruFocus rates ASX:VLS with a GF Score™ of 83/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 759 Drug Manufacturers companies, Vita Life Sciences ranks worse than 72.86% on this metric.
The historical rank and industry rank for Vita Life Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:
ASX:VLS'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.59 Med: 3.32 Max: 6.09
Current: 3.58
During the past 13 years, Vita Life Sciences's highest Cyclically Adjusted PB Ratio was 6.09. The lowest was 1.59. And the median was 3.32.
ASX:VLS's Cyclically Adjusted PB Ratio is ranked worse than 72.86% of 759
companies
in the Drug Manufacturers industry
Industry Median: 1.8
vs ASX:VLS: 3.58
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Vita Life Sciences's adjusted book value per share data of for the fiscal year that ended in Dec25 was A$1.014. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is A$0.69 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Vita Life Sciences (ASX:VLS) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Vita Life Sciences Cyclically Adjusted PB Ratio Related Terms
Vita Life Sciences Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences Cyclically Adjusted PB Ratio Chart
ASX:VLS vs ZTS, UTHR: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Cyclically Adjusted PB Ratio falls into.
Vita Life Sciences Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Vita Life Sciences's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 3.58 mean?
Vita Life Sciences (ASX:VLS) has a Cyclically Adjusted PB Ratio of 3.58 as of Jul. 04, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 3.32. Over the past decade, Vita Life Sciences' Cyclically Adjusted PB Ratio has ranged from 1.59 to 6.09. According to the industry distribution chart, Vita Life Sciences ranks #553 out of 759 companies in the Drug Manufacturers industry, placing it in the top 72.9%.
Is Vita Life Sciences' Cyclically Adjusted PB Ratio too high?
Vita Life Sciences' current Cyclically Adjusted PB Ratio of 3.58 is near median its 10-year median of 3.32. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 6.09. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.80. Vita Life Sciences' value of 3.58 is 98.9% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #553 out of 759 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Cyclically Adjusted PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #553 out of 759 companies for Cyclically Adjusted PB Ratio. This places Vita Life Sciences in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.80. Vita Life Sciences' value of 3.58 is 98.9% above this benchmark. Historically, Vita Life Sciences' own Cyclically Adjusted PB Ratio has ranged from 1.59 to 6.09 over the past decade. While the company's 10-year median is 3.32 vs. the industry median of 1.80, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.80, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Cyclically Adjusted PB Ratio of 3.58 is 98.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Cyclically Adjusted PB Ratio is 3.58, which is near median its own 10-year median of 3.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.47 — trading 0.4% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 3.58, which is near median its 10-year median of 3.32 and 98.9% above the Drug Manufacturers industry median of 1.80. Vita Life Sciences' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Cyclically Adjusted PB Ratio is 3.58 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.47 is trading 0.4% below its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Cyclically Adjusted PB Ratio: 3.58 (near median its 10-year median of 3.32)
GF Value™: A$2.48 vs. price of A$2.47 (0.4% below fair value)
Industry Position: 98.9% above the Drug Manufacturers median (#553 of 759)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
83GF Score
Get the complete analysis for ASX:VLS
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
